<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6286">
  <stage>Registered</stage>
  <submitdate>12/09/2016</submitdate>
  <approvaldate>12/09/2016</approvaldate>
  <nctid>NCT02947152</nctid>
  <trial_identification>
    <studytitle>HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma</studytitle>
    <scientifictitle>A Phase I, Multicenter, Open-label Dose Escalation and Expansion Study of HKT288, Administered Intravenously in Adult Patients With Advanced Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CHKT288X2101</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Epithelial Ovarian Cancer</healthcondition>
    <healthcondition>Renal Cell Carcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Non melanoma skin cancer</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Kidney</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Ovarian and primary peritoneal</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - HKT288

Experimental: Dose escalation part - Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer) and clear cell or papillary renal cell carcinoma

Experimental: Dose expansion part (RCC arm) - Includes patients with clear cell or papillary renal cell carcinoma

Experimental: Dose expansion part (ovarian cancer arm) - Includes patients with serous epithelial ovarian cancer (inclusive of fallopian tubal and peritoneal cancer)


Treatment: drugs: HKT288
Cadherin-6-targeting antibody-drug conjugate for intravenous administration

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of dose limiting toxicities (DLTs) in the DLT evaluation period</outcome>
      <timepoint>evaluation period is 21 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety assessed by overall incidence of adverse events (AEs) and serious adverse events (SAEs)</outcome>
      <timepoint>Until 105 days after last dose of study treatment (=average of approximately 6 months after first dose)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Tolerability as assessed by numbers of dose changes or interruptions</outcome>
      <timepoint>Until last dose of study treatment (=average of approximately 6 months after first dose)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety assessed by severity of adverse events (AEs) and serious adverse events (SAEs)</outcome>
      <timepoint>Until 105 days after last dose of study treatment (=average of approximately 6 months after first dose)</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Concentration vs. time profiles of total antibody (tAb)</outcome>
      <timepoint>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose). 1 cycle is 21 days, increases to 28 days if there is a dose delay of 7 days for the start of next dose</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Objective response rate</outcome>
      <timepoint>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Duration of response</outcome>
      <timepoint>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression-free survival</outcome>
      <timepoint>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Disease Control Rate</outcome>
      <timepoint>At 6 months on treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Best overall response</outcome>
      <timepoint>every 2 cycles up to Cycle 17 and every 3 cycles thereafter until study treatment discontinuation (=average of approximately 6 months after first dose). Then every 9 weeks until end of disease progression follow-up (up to 12 months)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Presence of anti-HKT288 antibodies.</outcome>
      <timepoint>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>CDH6 expression level</outcome>
      <timepoint>3 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics (PK) parameter (AUC) for HKT288</outcome>
      <timepoint>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter (Cmax) for HKT288</outcome>
      <timepoint>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameter (Tmax) for HKT288</outcome>
      <timepoint>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PK parameters (half-life) for HKT288</outcome>
      <timepoint>On treatment up to Cycle 6 Day 1 and at the time of study treatment discontinuation (=average of approximately 6 months after first dose)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Advanced (metastatic or locally advanced) serous epithelial ovarian, serous fallopian
             tubal or serous primary peritoneal cancer or advanced clear cell or papillary renal
             cell carcinoma who have received or are intolerant to all therapy known to confer
             clinical benefit for their disease, as determined by the investigator.

          -  Tumor sample is available for retrospective CDH6 expression testing

          -  Eastern Cooperative Oncology Group (ECOG) Performance status =2</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Patient has central nervous system metastatic involvement. Patients with previously
             treated CNS metastases are also excluded.

          -  Patient with any active or chronic corneal disorders

          -  Patients with monocular vision or have media opacities or any other condition that
             precludes monitoring of the retina or fundus.

          -  Patients with a history of serious allergic reactions

          -  Patients with QTcF &gt;470 msec at screening ECG or congenital long QT syndrome

          -  Any prior history of treatment with maytansine (DM1 or DM4)-based ADC

          -  Patient have received anti-cancer therapies within the following time frames prior to
             the first dose of study treatment:

               -  Conventional cytotoxic chemotherapy: =4 weeks (= 6 weeks for nitrosoureas and
                  mitomycin-C)

               -  Biologic therapy (e.g., antibodies): =4 weeks

               -  Non-cytotoxic small molecule therapeutics: =5 half-lives or =2 weeks (whichever
                  is longer)

               -  Other investigational agents: =4 weeks

               -  Radiation therapy (except for localized radiotherapy for analgesic purpose or for
                  lytic lesions at risk of fracture): =4 weeks

               -  Radiation therapy (localized radiotherapy for analgesic purpose or for lytic
                  lesions at risk of fracture) =2 weeks

               -  Major surgery: =2 weeks Other protocol defined inclusion/exclusion may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>120</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Suspended</recruitmentstatus>
    <anticipatedlastvisitdate>31/08/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Novartis Investigative Site - Melbourne</hospital>
    <postcode>3000 - Melbourne</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Leuven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Aichi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Catalunya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Locarno</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Novartis Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and
      renal cell carcinoma</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02947152</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Novartis Pharmaceuticals</name>
      <address>Novartis Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>